Image default

RETINA-AI Raises $5.2M for AI Detection of Diabetic Retinopathy

RETINA-AI Health, Inc. raised $5.2M in Series A financing for AI screening of diabetic retinopathy.

The capital was raised from private investors, 80% of whom are physicians. Also included amongst the investors are business titans such as Bill Smith, Founder of Shipt (acquired by Target in 2018).

RETINA-AI Health, Inc. has developed artificial intelligence technology to enable the diabetic retinal exam to be done in the primary care setting. The company’s HUMMINGBIRD DR 100™ is a cloud-based AI detector of diabetic retinopathy which interprets the retinal image and returns a PDF report within a few seconds.

RETINA-AI Health Inc.’s founder and CEO, Dr. Stephen Odaibo, a retina specialist, computer scientist, and full-stack AI engineer says the funds will be used to take the company’s retina-based AI detection technology through the FDA.

Dr. Richard Y. Hwang, MD, PhD, a retina specialist in El Paso, Texas, says, “artificial intelligence has the potential to make a significant impact in diabetic retinopathy screening by improving the efficiency, cost-effectiveness, and the accessibility of screening programs.”

Dr. Odaibo adds that “the confluence of value-based healthcare delivery and artificial intelligence provides a tangible and timely opportunity for positive impact.”

Related posts

C3 AI Reinvents No Code AI with the Introduction of C3 AI Ex Machina

AI TechPark

Wemlo introduces AI to mortgage processing

PR Newswire

Network Solutions Provider to Add CyGlass AI-based NDR in Portfolio

PR Newswire